Stream Therapy Device Rapidly Treats Chronic Wounds

The durable yet flexible watertight protective streaming device minimizes wound exposure to damaging elements while providing a controlled, moist environment for optimal receptiveness to the patented bioactive proteolytic enzyme ingredients. The device is based on continuous stream therapy (CST) technology, which streams an ongoing supply of fresh, bioactive solution to trigger the desired reaction, while actively and selectively draining, suctioning, and washing away the harmful exudates.

The device features an innovative combination of three cleansing actions responsive to the controlled wound environment. The combined cleansing action involves the continuous drainage of excess exudates, a mild negative pressure that achieves faster, proactive removal of necrotic burden, and a hypertonic medium for biochemical extraction of excess fluid. The three actions operate in concert to expedite treatment. The DermaStream device is available with highly active yet safe solutions specially developed for the debridement, regeneration, and closure phases of wound ýmanagement.

The DermaStream device is a product of EnzySurge (Rosh Ha'Ayin, Israel). While the U.S. Food and Drug Administration (FDA) has already approved the device itself, approval of the combined product with the chemical solution is still pending, as is European Community (CE) Marking approval.

"Chronic wounds are particularly hard to heal and require intensive, prolonged and expensive treatment, often involving hospitalization and surgical procedures,” said Professor Amihay Freeman, Ph.D., founder and chief scientist of EnzySurge, and the director of the Institute of Biotechnology of Tel-Aviv University (Israel). "EnzySurge offers a new treatment concept based on continuous irrigation of the wound with active biological solutions to significantly accelerate the healing process.”


Related Links:
EnzySurge
Tel-Aviv University